NCT03867331 - To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

May 21, 2020

Study Completion Date

May 21, 2020

Conditions

Malaria,Falciparum

Interventions

BIOLOGICAL

5 microgram VLPM01

VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

BIOLOGICAL

15 microgram VLPM01

VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

BIOLOGICAL

30 microgram VLPM01

VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.

OTHER

Plasmodium falciparum challenge

Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites

Trial Locations (1)

Walter Reed Army Institute of Research, Bethesda